77 related articles for article (PubMed ID: 26648017)
1. Methylsulfonylmethane inhibits HER2 expression through STAT5b in breast cancer cells.
Kang DY; Darvin P; Yoo YB; Joung YH; Sp N; Byun HJ; Yang YM
Int J Oncol; 2016 Feb; 48(2):836-42. PubMed ID: 26648017
[TBL] [Abstract][Full Text] [Related]
2. Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways.
Lim EJ; Hong DY; Park JH; Joung YH; Darvin P; Kim SY; Na YM; Hwang TS; Ye SK; Moon ES; Cho BW; Do Park K; Lee HK; Park T; Yang YM
PLoS One; 2012; 7(4):e33361. PubMed ID: 22485142
[TBL] [Abstract][Full Text] [Related]
3. The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.
S P N; Darvin P; Yoo YB; Joung YH; Kang DY; Kim DN; Hwang TS; Kim SY; Kim WS; Lee HK; Cho BW; Kim HS; Park KD; Park JH; Chang SH; Yang YM
BMC Cancer; 2015 Jun; 15():474. PubMed ID: 26084564
[TBL] [Abstract][Full Text] [Related]
4. MSM enhances GH signaling via the Jak2/STAT5b pathway in osteoblast-like cells and osteoblast differentiation through the activation of STAT5b in MSCs.
Joung YH; Lim EJ; Darvin P; Chung SC; Jang JW; Do Park K; Lee HK; Kim HS; Park T; Yang YM
PLoS One; 2012; 7(10):e47477. PubMed ID: 23071812
[TBL] [Abstract][Full Text] [Related]
5. Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway.
Joung YH; Na YM; Yoo YB; Darvin P; Sp N; Kang DY; Kim SY; Kim HS; Choi YH; Lee HK; Park KD; Cho BW; Kim HS; Park JH; Yang YM
Int J Oncol; 2014 Mar; 44(3):883-95. PubMed ID: 24402583
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
10. Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2-overexpressing cancer cells.
Do MT; Hwang YP; Kim HG; Na M; Jeong HG
J Cell Physiol; 2013 May; 228(5):1087-97. PubMed ID: 23065756
[TBL] [Abstract][Full Text] [Related]
11. Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells.
Nam JM; Jeon KH; Kwon H; Lee E; Jun KY; Jin YB; Lee YS; Na Y; Kwon Y
Eur J Pharm Sci; 2013 Oct; 50(2):181-90. PubMed ID: 23835029
[TBL] [Abstract][Full Text] [Related]
12. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
13. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
14. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K
Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B.
Joung YH; Lim EJ; Kim MS; Lim SD; Yoon SY; Lim YC; Yoo YB; Ye SK; Park T; Chung IM; Bae KY; Yang YM
Int J Oncol; 2008 Sep; 33(3):477-84. PubMed ID: 18695876
[TBL] [Abstract][Full Text] [Related]
16. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
17. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
[TBL] [Abstract][Full Text] [Related]
18. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
19. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
20. The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells.
Shi M; Liu D; Duan H; Qian L; Wang L; Niu L; Zhang H; Yong Z; Gong Z; Song L; Yu M; Hu M; Xia Q; Shen B; Guo N
Breast Cancer Res Treat; 2011 Jan; 125(2):351-62. PubMed ID: 20237834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
